Sihuan Pharmaceutical Holdings Group Ltd - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sihuan Pharmaceutical Holdings Group Ltd - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Sihuan Pharmaceutical Holdings Group Ltd - Product Pipeline Review - 2016', provides an overview of the Sihuan Pharmaceutical Holdings Group Ltd's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Sihuan Pharmaceutical Holdings Group Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Sihuan Pharmaceutical Holdings Group Ltd
- The report provides overview of Sihuan Pharmaceutical Holdings Group Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Sihuan Pharmaceutical Holdings Group Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Sihuan Pharmaceutical Holdings Group Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Sihuan Pharmaceutical Holdings Group Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Sihuan Pharmaceutical Holdings Group Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sihuan Pharmaceutical Holdings Group Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Sihuan Pharmaceutical Holdings Group Ltd Snapshot 6
Sihuan Pharmaceutical Holdings Group Ltd Overview 6
Key Facts 6
Sihuan Pharmaceutical Holdings Group Ltd - Research and Development Overview 7
Key Therapeutic Areas 7
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline Products Glance 13
Sihuan Pharmaceutical Holdings Group Ltd - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Sihuan Pharmaceutical Holdings Group Ltd - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Sihuan Pharmaceutical Holdings Group Ltd - Early Stage Pipeline Products 15
IND/CTA Filed Products/Combination Treatment Modalities 15
Preclinical Products/Combination Treatment Modalities 16
Sihuan Pharmaceutical Holdings Group Ltd - Unknown Stage Pipeline Products 17
Unknown Products/Combination Treatment Modalities 17
Sihuan Pharmaceutical Holdings Group Ltd - Drug Profiles 18
BR-01 - Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
cinepazide mesylate - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
cyclosporine - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
JK-05 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
levophencynonate hydrochloride - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
pinoxacin hydrochloride - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline Analysis 29
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline Products by Target 29
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline Products by Route of Administration 30
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline Products by Molecule Type 31
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline Products by Mechanism of Action 32
Sihuan Pharmaceutical Holdings Group Ltd - Dormant Projects 33
Sihuan Pharmaceutical Holdings Group Ltd - Discontinued Pipeline Products 34
Discontinued Pipeline Product Profiles 34
cyclosporine 34
Sihuan Pharmaceutical Holdings Group Ltd - Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

List of Tables

Sihuan Pharmaceutical Holdings Group Ltd, Key Facts 6
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline by Indication, 2016 8
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline by Stage of Development, 2016 9
Sihuan Pharmaceutical Holdings Group Ltd - Monotherapy Products in Pipeline, 2016 10
Sihuan Pharmaceutical Holdings Group Ltd - Partnered Products in Pipeline, 2016 11
Sihuan Pharmaceutical Holdings Group Ltd - Partnered Products/ Combination Treatment Modalities, 2016 12
Sihuan Pharmaceutical Holdings Group Ltd - Pre-Registration, 2016 13
Sihuan Pharmaceutical Holdings Group Ltd - Phase II, 2016 14
Sihuan Pharmaceutical Holdings Group Ltd - IND/CTA Filed, 2016 15
Sihuan Pharmaceutical Holdings Group Ltd - Preclinical, 2016 16
Sihuan Pharmaceutical Holdings Group Ltd - Unknown, 2016 17
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline by Target, 2016 29
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline by Route of Administration, 2016 30
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline by Molecule Type, 2016 31
Sihuan Pharmaceutical Holdings Group Ltd - Pipeline Products by Mechanism of Action, 2016 32
Sihuan Pharmaceutical Holdings Group Ltd - Dormant Developmental Projects,2016 33
Sihuan Pharmaceutical Holdings Group Ltd - Discontinued Pipeline Products, 2016 34
Sihuan Pharmaceutical Holdings Group Ltd, Subsidiaries 35